Search Results - "Eustace, Alex J"

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer by Roche, Sandra, Gaule, Patricia, Winrow, Deirdre, Mukherjee, Nupur, O'Neill, Fiona, Conlon, Neil T, Meiller, Justine, Collins, Denis M, Canonici, Alexandra, Fawsi, Mohammed Ibrahim, Estepa-Fernández, Alejandra, Madden, Stephen F, Crown, John, O'Donovan, Norma, Eustace, Alex J

“…Triple Negative Breast Cancer (TNBC), a subtype of breast cancer, has fewer successful therapeutic therapies than other types of breast cancer. Insulin-like…”
Get full text

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL by Eustace, Alex J, Conlon, Neil T, McDermott, Martina S J, Browne, Brigid C, O'Leary, Patrick, Holmes, Frankie A, Espina, Virginia, Liotta, Lance A, O'Shaughnessy, Joyce, Gallagher, Clair, O'Driscoll, Lorraine, Rani, Sweta, Madden, Stephen F, O'Brien, Neil A, Ginther, Charles, Slamon, Dennis, Walsh, Naomi, Gallagher, William M, Zagozdzon, Radoslaw, Watson, William R, O'Donovan, Norma, Crown, John

“…Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop…”
Get full text

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines by Eustace, Alex J, Crown, John, Clynes, Martin, O'Donovan, Norma

“…Metastatic melanoma is a highly chemotherapy resistant tumour. The use of newer targeted therapies alone and in combination with chemotherapy may offer new…”
Get full text

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells by Glynn, Sharon A, O'Sullivan, Dermot, Eustace, Alex J, Clynes, Martin, O'Donovan, Norma

“…A number of recent studies have suggested that cancer incidence rates may be lower in patients receiving statin treatment for hypercholesterolemia. We examined…”
Get full text

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer by Canonici, Alexandra, Browne, Alacoque L., Ibrahim, Mohamed F. K., Fanning, Kevin P., Roche, Sandra, Conlon, Neil T., O’Neill, Fiona, Meiller, Justine, Cremona, Mattia, Morgan, Clare, Hennessy, Bryan T., Eustace, Alex J., Solca, Flavio, O’Donovan, Norma, Crown, John

“…Background: Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited therapeutic options. Epidermal growth factor receptor…”
Get full text

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial by Gullo, Giuseppe, Eustace, Alex J., Canonici, Alexandra, Collins, Denis M., Kennedy, Michael J., Grogan, Liam, Breathhnach, Oscar, McCaffrey, John, Keane, Maccon, Martin, Michael J., Gupta, Rajnish, Leonard, Gregory, O’Connor, Miriam, Calvert, Paula M., Donnellan, Paul, Walshe, Janice, McDermott, Enda, Scott, Kathleen, Hernando, Andres, Parker, Imelda, Murray, David W., O’Farrell, Alice C., Maratha, Ashwini, Dicker, Patrick, Rafferty, Mairin, Murphy, Verena, O’Donovan, Norma, Gallagher, William M., Ky, Bonnie, Tryfonopoulos, Dimitrios, Moulton, Brian, Byrne, Annette T., Crown, John

“…Background: Combining bevacizumab and chemotherapy produced superior response rates compared with chemotherapy alone in metastatic breast cancer. As…”
Get full text

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer by Cosgrove, Nicola, Eustace, Alex J., O’Donovan, Peter, Madden, Stephen F., Moran, Bruce, Crown, John, Moulton, Brian, Morris, Patrick G., Grogan, Liam, Breathnach, Oscar, Power, Colm, Allen, Michael, Walshe, Janice M., Hill, Arnold D., Blümel, Anna, O’Connor, Darren, Das, Sudipto, Milewska, Małgorzata, Fay, Joanna, Kay, Elaine, Toomey, Sinead, Hennessy, Bryan T., Furney, Simon J.

“…HER2-positive (HER2+) breast cancer accounts for 20–25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better…”
Get full text

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers by Milewska, Malgorzata, Cremona, Mattia, Morgan, Clare, O’Shea, John, Carr, Aoife, Vellanki, Sri HariKrishna, Hopkins, Ann M., Toomey, Sinead, Madden, Stephen F., Hennessy, Bryan T., Eustace, Alex J.

“…Background: The application of genomic technologies to patient tumor samples identified groups of signaling pathways which acquire activating mutations. Some…”
Get full text

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies by McDermott, Martina, Eustace, Alex J, Busschots, Steven, Breen, Laura, Crown, John, Clynes, Martin, O'Donovan, Norma, Stordal, Britta

“…The development of a drug-resistant cell line can take from 3 to 18 months. However, little is published on the methodology of this development process. This…”
Get full text

Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer by Collins, Denis M, Madden, Stephen F, Gaynor, Nicola, AlSultan, Dalal, Le Gal, Marion, Eustace, Alex J, Gately, Kathy A, Hughes, Clare, Davies, Anthony M, Mahgoub, Thamir, Ballot, Jo, Toomey, Sinead, O'Connor, Darran P, Gallagher, William M, Holmes, Frankie A, Espina, Virginia, Liotta, Lance, Hennessy, Bryan T, O'Byrne, Kenneth J, Hasmann, Max, Bossenmaier, Birgit, O'Donovan, Norma, Crown, John

“…Antibody-dependent cell-mediated cytotoxicity (ADCC) is one mechanism of action of the monoclonal antibody (mAb) therapies trastuzumab and pertuzumab. Tyrosine…”
Get full text

Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer by Kennedy, Sean P., O’Neill, Michael, Cunningham, Darren, Morris, Patrick G., Toomey, Sinead, Blanco-Aparicio, Carmen, Martinez, Sonia, Pastor, Joaquin, Eustace, Alex J., Hennessy, Bryan T.

“…The proviral integration of Moloney virus (PIM) family of protein kinases are overexpressed in many haematological and solid tumours. PIM kinase expression is…”
Get full text

Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy by Gaynor, Nicola, Blanco, Alfonso, Madden, Stephen F., Moran, Barry, Fletcher, Jean M., Kaukonen, Damien, Ramírez, Javier Sánchez, Eustace, Alex J., McDermott, Martina S. J., Canonici, Alexandra, Toomey, Sinead, Teiserskiene, Ausra, Hennessy, Bryan T., O’Donovan, Norma, Crown, John, Collins, Denis M.

“…Background The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy in combination with trastuzumab, lapatinib or both in…”
Get full text

Predictive biomarkers for dasatinib treatment in melanoma by Eustace, Alex J, Kennedy, Susan, Larkin, Anne-Marie, Mahgoub, Thamir, Tryfonopoulos, Dimitrios, O'Driscoll, Lorraine, Clynes, Martin, Crown, John, O'Donovan, Norma

“…Dasatinib has anti-proliferative and anti-invasive effects in melanoma cell lines. However clinical trials have shown modest activity for dasatinib in…”
Get full text

Precision Oncology, Artificial Intelligence, and Novel Therapeutic Advancements in the Diagnosis, Prevention, and Treatment of Cancer: Highlights from the 59th Irish Association for Cancer Research (IACR) Annual Conference by Lynch, Seodhna M, Heeran, Aisling B, Burke, Caoimbhe, Lynam-Lennon, Niamh, Eustace, Alex J, Dean, Kellie, Robson, Tracy, Rahman, Arman, Marcone, Simone

“…Advancements in oncology, especially with the era of precision oncology, is resulting in a paradigm shift in cancer care. Indeed, innovative technologies, such…”
Get full text

Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference by Kennedy, Sean P, Treacy, Oliver, Allott, Emma H, Eustace, Alex J, Lynam-Lennon, Niamh, Buckley, Niamh, Robson, Tracy

“…Innovation in both detection and treatment of cancer is necessary for the constant improvement in therapeutic strategies, especially in patients with novel or…”
Get full text

The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells by AlSultan, Dalal, Kavanagh, Emma, O’Grady, Shane, Eustace, Alex J, Castell, Alina, Larsson, Lars-Gunnar, Crown, John, Madden, Stephen F, Duffy, Michael J

“…Summary Background The MYC oncogene is one of the most frequently altered driver genes in cancer. MYC is thus a potential target for cancer treatment as well…”
Get full text

Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A by Breen, Laura, Gaule, Patricia B., Canonici, Alexandra, Walsh, Naomi, Collins, Denis M., Cremona, Mattia, Hennessy, Bryan T., Duffy, Michael J., Crown, John, Donovan, Norma O’, Eustace, Alex J.

“…Summary Introduction Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer that carries a poorer prognosis. There remains a…”
Get full text

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells by Canonici, Alexandra, Qadir, Zulfiqar, Conlon, Neil T., Collins, Denis M., O’Brien, Neil A., Walsh, Naomi, Eustace, Alex J., O’Donovan, Norma, Crown, John

“…Summary As HER2 is a client protein of the molecular chaperone Hsp90, targeting Hsp90 may be beneficial in HER2-positive breast cancer. In this study, the…”
Get full text

Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer by Eustace, Alex J., Lee, Min Jie, Colley, Grace, Roban, Jack, Downing, Tim, Buchanan, Paul J.

“…Triple-negative breast cancer (TNBC) is characterized as an aggressive form of breast cancer (BC) associated with poor patient outcomes. For the majority of…”
Get full text

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells by Gaule, Patricia, Mukherjee, Nupur, Corkery, Brendan, Eustace, Alex J, Gately, Kathy, Roche, Sandra, O'Connor, Robert, O'Byrne, Kenneth J, Walsh, Naomi, Duffy, Michael J, Crown, John, O'Donovan, Norma

“…In pre-clinical studies, triple-negative breast cancer (TNBC) cells have demonstrated sensitivity to the multi-targeted kinase inhibitor dasatinib; however,…”
Get full text